Birch Hill Investment Advisors LLC Purchases 3,988 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Birch Hill Investment Advisors LLC increased its holdings in Edwards Lifesciences Corporation by acquiring 3,988 shares, bringing their total ownership to approximately 760,587 shares, valued at around $59.49 million.
• Edwards Lifesciences reported a quarterly earnings of $0.67 per share, exceeding estimates of $0.62, with revenue reaching $1.53 billion, up 11.9% year-over-year.
• Analysts have varied ratings and target prices for Edwards Lifesciences, with Barclays raising the target price to $95.00 and three analysts rating it as a "Strong Buy."

Birch Hill Investment Advisors LLC raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 0.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 760,587 shares of the medical research company's stock after acquiring an additional 3,988 shares during the period. Edwards Lifesciences makes up about 2.6% of Birch Hill Investment Advisors LLC's investment portfolio, making the stock its 16th largest position. Birch Hill Investment Advisors LLC owned 0.13% of Edwards Lifesciences worth $59,486,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after purchasing an additional 145 shares during the period. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at $1,760,000. Czech National Bank boosted its stake in shares of Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock valued at $11,214,000 after purchasing an additional 7,917 shares during the period. Mirova US LLC boosted its stake in shares of Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company's stock valued at $229,257,000 after purchasing an additional 1,054,301 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after purchasing an additional 9,188 shares during the period. Institutional investors own 79.46% of the company's stock.

Insider Activity

In other news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Performance

EW stock opened at $76.03 on Wednesday. The firm has a market cap of $44.64 billion, a price-to-earnings ratio of 10.94, a PEG ratio of 3.61 and a beta of 1.05. The firm has a 50-day simple moving average of $77.46 and a two-hundred day simple moving average of $76.25. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EW. Barclays boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Oppenheimer lowered shares of Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a research note on Wednesday, October 8th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Finally, BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research note on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus target price of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.